Hope for rare bone disease: experimental drug offered to trial graduates
NCT ID NCT07301450
Summary
This program provides continued access to the experimental drug garetosmab for approximately 55 adults worldwide with Fibrodysplasia Ossificans Progressiva (FOP), a rare and debilitating condition where muscles and connective tissues turn into bone. Participants must have completed the main treatment period of a previous clinical trial called OPTIMA. The goal is to control disease progression and reduce abnormal bone formation while awaiting potential regulatory approval.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.